McKesson Corp (MCK) reported robust financial results for the second quarter of fiscal 2026, surpassing analyst expectations. The company posted earnings per share (EPS) of $9.86, significantly exceeding the consensus estimate of $9.13 by $0.73. However, revenue for the quarter came in at $103.2 billion, falling short of the anticipated $105.2 billion.
This earnings report provides insight into McKesson's operational performance and financial health within the health care industry. The company, headquartered in Irving, Texas, employs 43,000 full-time staff and engages in providing healthcare services across multiple segments, including U.S. Pharmaceuticals and Medical-Surgical Solutions.
Investors will have the opportunity to gain further insights during the upcoming earnings conference call scheduled for after market close. This discussion will likely address business performance and future outlook, providing essential context for stakeholders.
As of November 8, 2025, McKesson holds a market capitalization of $106.5 billion, with a trailing twelve months (TTM) price-to-earnings ratio of 33.66 and an EPS of 25.06. The company is expected to report its next earnings on May 5, 2026, with EPS estimated at 11.3066 and revenue at $102.2 billion.